Listed

Hyperion Defi, Inc.: Form 10-Q for the period ended Sep 30, 2018

Filed with the SEC on Nov 13, 2018 and accepted by EDGAR at Nov 13, 2018, 15:42 ET.

Share

Management's discussion and analysis

As filed, 16,973 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The following discussion and analysis of the results of operations and financial condition of Eyenovia, Inc. (“Eyenovia,” the “Company,” “we,” “us” and “our”) as of September 30, 2018 and for the three and nine months ended September 30, 2018 and 2017 should be read in conjunction with our unaudited financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q and with our audited financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2017 as filed with the Securities and Exchange Commission (“SEC”) on April 2, 2018.

Forward Looking Statements

This report contains “forward-looking statements.” Specifically, all statements other than statements of historical facts included in this report, including regarding our financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. These forward-looking statements are based on the beliefs of management at the time these statements were made, as well as assumptions made by and information currently available to management. When used in this report, the words “anticipate,” “believe,” “estimate,” “expect,” “may,” “might,” “will,” “continue” “intend,” and “plan” and words or phrases of similar import are intended to identify forward-looking statements. These statements reflect our current view with respect to future events and are subject to risks, uncertainties and assumptions related to various factors that could cause actual results and the timing of events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section titled “Risk Factors” included in our most recent Annual report on Form 10-K filed with the SEC. Furthermore, such forward-looking statements speak only as of this Quarterly Report on Form 10-Q. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.

Overview

We are a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing our patented piezo-print technology, which we recently branded the Optejet™, to deliver micro-doses (6–8 µL) of active pharmaceutical ingredients, or micro-therapeutics, topically to the eye. This micro-dosing technology has the potential to replace traditional macro-dosing applications (e.g. conventional eye droppers) that routinely overdose or under-dose when used in the topical administration of ophthalmic therapeutics. We believe our micro-therapeutic product candidates may be able to achieve similar pharmacologic effects as traditional macro-dosing applications while reducing the adverse effects associated with these techniques. We have received written FDA feedback indicating that we can proceed to Phase III clinical trials for two of our lead programs: MicroProst, a novel micro-therapeutic latanoprost formulation for Chronic Angle Closure Glaucoma (CACG), an indication with no FDA-approved drug treatments; and MicroStat, a fixed combination of micro-therapeutic phenylephrine-tropicamide formulation for mydriasis, also known as pupil dilation for use in eye exams. MicroTears, our OTC product candidate for dry eye, will not require Phase III clinical trials, and we plan to proceed with registration activities.

We have completed two Phase II clinical trials, treating more than 110 subjects, with results published in peer-reviewed literature. Applying multiple front-of-the-eye (the area in front of the lens) formulations in subjects for mydriasis, our piezo-print technology delivered microliter precision at the volume of the eye’s natural tear film capacity of 6–8 µL, which reduced ocular and systemic drug and preservative exposure when compared to eye drops, resulting in comparable efficacy with fewer side effects. We believe that these clinical trials support our advancement into late stage clinical trials utilizing the 505(b)(2) pathway. We intend to use this pathway for future clinical trials in new indications with significant unmet needs. We plan to commence Phase III clinical trials for MicroProst in the first half of 2019, pending IND submission and FDA feedback, and MicroStat later this November.

We have not completed development of any product candidate and we have therefore not generated any revenues from product sales.

Historically, we have financed our operations principally through private placements of preferred stock as well as our initial public offering that closed in January 2018. Although it is difficult to predict our liquidity requirements, based upon our current operating plan, we believe we will have sufficient cash to meet our projected operating requirements for at least the next twelve months. Thereafter, the Company will need to raise further capital, through the sale of additional equity or debt securities or otherwise, to support its future operations. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs.

Our net losses were $4.3 million and $11.1 million for the three and nine months ended September 30, 2018, respectively. As of September 30, 2018, we had working capital and an accumulated deficit of $19.6 million and $30.3 million, respectively.

Financial Overview

Revenue

We have not generated any revenue from product sales since our inception and do not expect to generate any revenue from the sale of products in the near future. Our ability to generate revenues will depend heavily on the successful development, regulatory approval and commercialization of our micro-therapeutic product candidates.

Research and Development Expenses

Research and development expenses are incurred in connection with the research and development of our micro-therapeutics and consist primarily of contract service expenses. Given where we are in our life cycle, we do not separately track research and development expenses by project. Our research and development expenses consist of:

  • direct clinical and non-clinical expenses, which include expenses incurred under agreements with contract research and contract manufacturing organizations, and costs associated with preclinical, development and regulatory activities;
  • personnel-related expenses, which include expenses related to consulting agreements with individuals that have since entered into employment agreements with us as well as salaries and other compensation of employees that are attributable to research and development activities; and
  • facilities and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, marketing, insurance and supplies used in research and development activities.

We expense research and development costs as incurred. We record costs for some development activities, such as clinical trials, based on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, clinical site activations or other information our vendors provide to us.

We expect that our research and development expenses will increase with the continuation of the aforementioned initiatives.

General and Administrative Expenses

General and administrative expenses consist primarily of payroll and related expenses, legal and other professional services, as well as non-cash stock-based compensation expense. We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued research and development and the potential commercialization of our product candidates. We also anticipate increased expenses related to audit, legal, regulatory, and tax-related services associated with maintaining compliance with exchange listing and SEC requirements. In addition, director and officer insurance premiums and investor relations costs associated with being a public company are expected to increase in future periods.

Results of Operations

Three Months Ended September 30, 2018 Compared with Three Months Ended September 30, 2017

Research and Development Expenses

Research and development expenses for the three months ended September 30, 2018 totaled $2.5 million, an increase of $1.9 million, or 336%, as compared to $0.6 million recorded for the three months ended September 30, 2017. Research and development expenses consisted of the following:

For the Three Months Ended September 30, 2018 2017
Direct clinical and non-clinical expenses $1,241,505 $318,986
Personnel-related expenses 675,258 50,944
Non-cash stock-based compensation expenses 240,432 128,092
Facilities and other expenses 330,378 72,400
Total research and development expenses $2,487,573 $570,422

14

The increase in direct clinical and non-clinical expenses, facilities and other expenses and personnel-related expenses is primarily due to an increase in contracted services, supplies and the hiring of 13 additional employees as we expanded our research and development activities for our micro-therapeutic products. For the three months ended September 30, 2018, personnel-related expenses include approximately $0.1 million of estimated expenses in connection with year-end 2018 executive bonuses that are yet to be paid. The increase in non-cash stock-based compensation expense as compared to the 2017 period was due to additional stock options that were granted in 2018.

General and Administrative Expenses

General and administrative expense for the three months ended September 30, 2018 totaled $1.8 million, an increase of $1.5 million, or 482%, as compared to $0.3 million recorded for the three months ended September 30, 2017. This increase is primarily attributable to an increase in expenses related to legal and professional fees of $0.6 million, payroll and contracted services of $0.4 million (including approximately $0.1 million of estimated expenses in connection with year-end 2018 executive bonuses that are yet to be paid), non-cash stock-based compensation, insurance, and rent expense of $0.3 million, as well as costs related to being a public company of $0.1 million. It also was largely due to the hiring of an additional five employees associated with the growth of our business as well as costs related to being a public company.

Nine Months Ended September 30, 2018 Compared with Nine Months Ended September 30, 2017

Research and Development Expenses

Research and development expenses for the nine months ended September 30, 2018 totaled $7.0 million, an increase of $4.8 million, or 213%, as compared to $2.2 million recorded for the nine months ended September 30, 2017. Research and development expenses consisted of the following:

For the Nine Months Ended September 30, 2018 2017
Direct clinical and non-clinical expenses $3,430,895 $1,909,975
Personnel-related expenses 1,726,250 68,073
Non-cash stock-based compensation expenses 556,722 134,482
Facilities and other expenses 1,279,965 120,663
Total research and development expenses $6,993,832 $2,233,193

The increase in direct clinical and non-clinical expenses, facilities and other expenses and personnel-related expenses is primarily due to an increase in contracted services, supplies and the hiring of 13 additional employees as we expanded our research and development activities for our micro-therapeutic products. For nine months ended September 30, 2018, personnel-related expenses include approximately $0.2 million of estimated expenses in connection with year-end 2018 executive bonuses that are yet to be paid. The increase in non-cash stock-based compensation expense as compared to the 2017 period was due to additional stock options that were granted in 2018.

General and Administrative Expenses

General and administrative expense for the nine months ended September 30, 2018 totaled $4.1 million, an increase of $3.4 million, or 454%, as compared to $0.7 million recorded for the nine months ended September 30, 2017. This increase was primarily attributable to an increase in legal and professional fees of $1.3 million, expenses related to payroll and contracted services of $0.8 million (including approximately $0.2 million of estimated expenses in connection with year-end 2018 executive bonuses that are yet to be paid), non-cash stock-based compensation costs of $0.5 million, and insurance expense of $0.3 million as compared to 2017. It also was largely due to the hiring of an additional five employees associated with the growth of our business as well as costs related to being a public company.

Liquidity and Capital Resources

Since inception, we have experienced negative cash flows from operations. At September 30, 2018, our accumulated deficit since inception was $30.3 million. In January 2018, we raised aggregate net proceeds of $24.7 million in our initial public offering.

At September 30, 2018, we had total working capital and stockholders’ equity of $19.6 million and $19.7 million, respectively.

At September 30, 2018 and December 31, 2017, we had no debt outstanding.

At September 30, 2018, we had a cash balance of $21.0 million. We expect our current cash on hand to be sufficient to meet our operating and capital requirements for at least the next twelve months. Thereafter, we will likely need to raise further capital, through the sale of additional equity or debt securities, or otherwise, to support our future operations. Our operating needs include the planned costs to operate our business, including amounts required to fund research and development activities including clinical studies, working capital and capital expenditures. Our future capital requirements and the adequacy of our available funds will depend on many factors, including our ability to successfully commercialize our products and services, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement our product and service offerings. If we are unable to secure additional capital, we may be required to curtail our research and development initiatives and take additional measures to reduce costs in order to conserve our cash.

During the nine months ended September 30, 2018 and 2017, our sources and uses of cash were as follows:

Net cash used in operating activities for the nine months ended September 30, 2018 was $9.0 million, which includes cash used to fund a net loss of $11.1 million, reduced by $1.1 million of non-cash stock-based compensation, and partially offset by $0.9 million of cash provided by changes in operating assets and liabilities. Net cash used in operating activities for the nine months ended September 30, 2017 was approximately $2.7 million, which includes cash used from a net loss of approximately $3.0 million, reduced by non-cash charges of approximately $0.2 million.

There were no cash flows from investing activities for the nine months ended September 30, 2018. Cash used in investing activities was approximately $3,000 for the nine months ended September 30, 2017 for purchases of property and equipment.

Cash provided by financing activities for the nine months ended September 30, 2018 totaled $24.8 million, which was primarily attributable to $25.1 million of proceeds from the sale of common stock in our initial public offering, reduced by issuance costs related to our initial public offering of $0.3 million. Cash provided from financing activities for the nine months ended September 30, 2017 totaled approximately $6.8 million, which primarily came from the sale of Series B convertible preferred stock.

Off-Balance Sheet Arrangements

There are no off-balance sheet arrangements between us and any other entity that have, or are reasonably likely to have, a current or future effect on financial conditions, changes in financial conditions, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.

Critical Accounting Policies

For a description of our critical accounting policies, see Note 2 – Summary of Significant Accounting Policies in Part 1, Item 1 of this Quarterly Report on Form 10-Q.

Recently Adopted Accounting Pronouncements

For a description of adopted accounting pronouncements, including adoption dates and estimated effects, if any, on our consolidated financial statements, see Note 2 – Summary of Significant Accounting Policies in Part 1, Item 1 of this Quarterly Report on Form 10-Q.

Controls and procedures

As filed, 4,114 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this Quarterly Report on Form 10-Q, we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial and accounting officer, of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based on the foregoing evaluation, our principal executive officer and principal financial and accounting officer concluded that, as of September 30, 2018, our disclosure controls and procedures were not effective to provide reasonable assurance that the information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and is accumulated and communicated to our management, including our principal executive officer, as appropriate, to allow timely decisions regarding required disclosure.

Our Annual Report on Form 10-K did not include a report of management’s assessment regarding internal control over financial reporting as of December 31, 2017 or an attestation report of our registered public accounting firm due to a transition period established by the rules of the SEC for newly public companies and emerging growth companies, as applicable. However, as previously disclosed, the following material weaknesses in our internal control over financial reporting were identified as of December 31, 2017 in the normal course and continued to exist as of September 30, 2018:

1. We had insufficient segregation of duties in our finance and accounting function because of our limited personnel.

2. We did not properly identify all related party relationships and transactions so that they could be evaluated for disclosure in our public filings.

3. The terms of certain agreements entered into by us were not properly communicated to the Board of Directors in order for the Board of Directors to take the appropriate actions.

4. We did not adequately record research and development expenses in our internal books and records to permit timely and accurate financial reporting.

A material weakness is a deficiency, or a combination of deficiencies, within the meaning of Public Company Accounting Oversight Board (“PCAOB”) Auditing Standard AS 2201, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company's annual or interim financial statements will not be prevented or detected on a timely basis.

Remediation

We continue the implementation of our remediation plan and to date we have, among other things, (a) increased the oversight and review procedures of the Board of Directors and its Audit Committee with regard to financial reporting, financial processes and procedures and internal control procedures and (b) hired additional finance and accounting personnel, including a Chief Financial Officer (hired December 2017), who will assist in the process of remediating the weaknesses identified above. In April 2018, the Board of Directors also adopted a related party transaction policy. In July 2018, we implemented an enhanced chart of accounts designed to facilitate the timely and accurate financial reporting of research and development expenses. In September and October 2018, we implemented additional controls, including regarding disclosure procedures, such that, as of the date of this filing, our management believes that the controls implemented to-date are sufficient to address all of the weaknesses described above. However, no assurances that our remediation is effective can be made until remedial controls operate for a period of time.

Changes in Internal Control over Financial Reporting

Except as disclosed above, our internal control over financial reporting did not change during the three months ended September 30, 2018.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2018-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2018-07-01 to 2018-09-30$2.5mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2018-01-01 to 2018-09-30$7.0mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2018-07-01 to 2018-09-30−$4.3mus-gaap:OperatingIncomeLoss
Operating income9 months2018-01-01 to 2018-09-30−$11.1mus-gaap:OperatingIncomeLoss
Net income3 months2018-07-01 to 2018-09-30−$4.3mus-gaap:NetIncomeLoss
Net income9 months2018-01-01 to 2018-09-30−$11.1mus-gaap:NetIncomeLoss
Diluted EPS3 months2018-07-01 to 2018-09-30−$0.43us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS9 months2018-01-01 to 2018-09-30−$1.20us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow9 months2018-01-01 to 2018-09-30−$9.0mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2018-01-01 to 2018-09-30$0us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2018-09-30$21.0mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2018-09-30$21.3mus-gaap:AssetsCurrent
Total assetsAt period end2018-09-30$21.5mus-gaap:Assets
Current liabilitiesAt period end2018-09-30$1.7mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2018-09-30$1.7mus-gaap:Liabilities
Shareholders' equityAt period end2018-09-30$19.7mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001144204-18-059318. Last ingested by Listed: Nov 14, 2026, 10:51 ET. Listed shows no prices and gives no investment advice.